Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Post-450 day durable response

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Aug 01, 2024 1:29pm

298 Views

Post# 36158633

RE:Post-450 day durable response

I share that view Eoganacht. If your hunch is correct & based on our competition's data, a BTD is a foregone conclusion imo...simply need to jump through the FDA hoops.

Per Pink Sheet US FDA Performance Tracker (data up to 2021), oncology therapeutics have outperformed other therapeutic categories. Roughly two-thirds of BTD designations in the oncology space had resulted in FDA approvals. Having a solidly supported BTD is pretty exclusive, & I believe it will be our golden ticket to commercialization. JMO.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing